Grifols SA (GRLS)

15.385
-0.200(-1.28%)
  • Volume:
    1,379,104
  • Bid/Ask:
    15.335/15.435
  • Day's Range:
    15.332 - 15.707
  • Type:Equity
  • Market:Spain
  • ISIN:ES0171996087

GRLS Overview

Prev. Close
15.385
Day's Range
15.332-15.707
Revenue
5.2B
Open
15.678
52 wk Range
15.33-26.07
EPS
0.98
Volume
1,379,104
Market Cap
10.5B
Dividend (Yield)
0.36
(2.18%)
Average Vol. (3m)
1,021,636
P/E Ratio
16.99
Beta
0.13
1-Year Change
-35.52%
Shares Outstanding
682,484,378
Next Earnings Date
Mar 03, 2022
What is your sentiment on Grifols SA?
or
Market is currently closed. Voting is open during market hours.

Grifols SA Company Profile

Employees
23431
Market
Spain

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • dan ganas de comprar
    0
    • Also has joined that issue with more investments and more debt...
      0
      • The issue with GRIFOLS seems to relate with FCF problems, caused by minor disposal of certain substances (including blood), in regard of coronavirus. Lately is reported George Soros made a little investment in GRLS. I think is a good company in bad times... Greetings!
        0
        • Bought some more today even if I missed the early morning opportunity of buying at 19.53
          0
          • What’s happening with this Company?...
            0
            • to the roof 🚀
              0
            • armand baucells castells Yes! It was, and it is, ridiculously CHEAP!
              0
            • NADIE LO SABE
              0
          • Down to 16.27 euros?
            2
            • Ahh seems it lost support on the 22.60 area, heading down to 21.6 in my opinion, let's hope for a bounce up from there
              0
              • Upps!
                0
                • I meant 24.19 ... I am still bullish on the long run for Grifols
                  0
                  • I just bought some more GRF at 21.19
                    0
                    • With vaccine announced by Moderna, how do you think will react Grifols? Up or Down, because his earnings beat forecasts but has not been too much bullish.
                      0
                      • Do you know what,s the reason of this falling?
                        0
                        • Grifols  has entered into an agreement to acquire the remaining equity of Alkahest in exchange for a total price of $146M, on a debt-free basis. No additional financing will be required.The transaction is expected to close in early 2021
                          0
                          • to the moon baby, to the moon
                            0
                            • Alguien sabe a que se debe el subidon de la cotizacion de Grifols hoy?
                              0
                              • al pinchazo de Vertex
                                0
                            • Por fin!!!!!! Breaking 25$
                              0
                              • target 28
                                0
                                • breaking $24 today!
                                  0
                                  • is worth to entry to GRLS ? any opinion please ?
                                    0
                                    • El precio cayendo con decremento de volumen es un síntoma potencialmente alcista. R 25.2€
                                      0
                                      • do you think Mrs. Pilar will go up again soon ? best regards.
                                        0
                                    • at 25 ferst upp
                                      0
                                      • Dear Juan is it worth to entry in Grifols please ? what is your opinion please ?
                                        0
                                    • a promising growth company
                                      0
                                      • do you think Mr. Trau it worths to entry in side inside ? in Grifols please ?
                                        0
                                    • Soros in, me out
                                      3
                                      • Dear Emilo George Soros is inside ? is it worth to entry in this equity in Grifols please ?
                                        0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.